Table 1 |
|
|
Revised Scoring System for the Diagnosis of Autoimmune Hepatitis6. |
|
| Parameter/Features |
Score |
|
|
|
| Gender |
|
| - Female/Male |
+2/0 |
| Degree of elevation above upper normal limit of ALP vs. aminotransferases |
|
| - <1.5 |
+2 |
| - 1.5 – 3.0 |
0 |
| - >3.0 |
-2 |
| Total serum globulins, γ-globulins, or IgG above normal |
|
| - >2.0 |
+3 |
| - 1.5 – 2.0 |
+2 |
| - 1.0 – 1.5 |
+1 |
| - <1.0 |
0 |
| ANA, SMA or LKM-1 (titers by immunofluorescence on rodent tissues or HEp2-cells) |
|
| - >1 : 80 |
+3 |
| - 1 : 80 |
+2 |
| - 1 : 40 |
+1 |
| - <1 : 40 |
0 |
| - AMA positive |
-4 |
| Hepatitis viral markers (IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV and HCV-RNA) |
|
| - Positive/Negative |
-3/+3 |
| Recent or current use of known or suspected hepatotoxic drugs |
|
| - Yes/No |
-4/+1 |
| Average alcohol intake |
|
| - <25 g/day |
+2 |
| - >60 g/day |
-2 |
| Other autoimmune disease(s) in patient or first degree relatives |
|
| - Yes/No |
+2/0 |
| Optional additional parameters (should be allocated only if ANA, SMA or LKM-1 are
negative) |
|
| - HLA DR3, DR4, or other HLA with published association with AIH) |
+1 |
| - Seropositivity for any of ANCA, anti-LC1, anti-SLA/LP, anti-ASGPR and anti-sulfatide |
+2 |
| Liver histology |
|
| - Interface hepatitis |
+3 |
| - Predominant lymphoplasmacytic infiltrate |
+1 |
| - Rosetting of liver cells |
+1 |
| - None of the above |
-5 |
| - Biliary changes |
-3 |
| - Other changes |
-3 |
| Response to therapy (as defined in Table 2) |
|
| - Complete/Relapse |
+2/+3 |
|
|
|
|
Definite AIH if greater than 15 before treatment or greater than 17 post-treatment; probable AIH if varies between 10–15 before treatment or 12–17 post-treatment. ALP: alkaline phospatase, IgM anti-HAV: hepatitis A virus IgM antibody, anti-HCV: hepatitis C virus antibody, HBsAg: surface antigen of hepatitis B virus, IgM anti-HBc: IgM antibody against the nuclear antigen of hepatitis B virus. Other abbreviations are the same as shown in the text. |
|
|
Zachou et al. Journal of Autoimmune Diseases 2004 1:2 doi:10.1186/1740-2557-1-2 |
|
